{"id":4625,"date":"2025-03-31T18:12:14","date_gmt":"2025-03-31T18:12:14","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/phosphate-supplements-txt\/"},"modified":"2025-03-31T18:12:14","modified_gmt":"2025-03-31T18:12:14","slug":"phosphate-supplements-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/phosphate-supplements-txt\/","title":{"rendered":"phosphate supplements.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nHypophosphataemia

DOSE IN NORMAL RENAL FUNCTION <\/H3>Oral: According to response; maximum oral dose =100 mmol in 24 hoursIV: 9\u201330 mmol\/day (maximum 500 micromols\/kg in critically ill patients); see \u2018Other Information\u2019

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :94\u201397 (Phosphate)<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :No data<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : High<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :No data<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :No data

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Dialysed. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Dose as in normal renal function
  • HDF\/high flux &nbsp :Dialysed. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugsAvoid insoluble incompatibilities, e.g. calcium salts

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>IV, oral

    Rate of Administration <\/H4>Usually over 6\u201312 hours

    Comments<\/H4>Phosphate polyfusor: give undiluted over 24 hours, peripherallyAddiphos: peripherally \u2013 give each vial (20 mL) diluted to 250\u2013500 mL with glucose 5% over 6\u201312 hours, minimum volume 100 mL (UK Critical Care Group, Minimum Infusion Volumes for fluid restricted critically ill patients, 3rd Edition, 2006); centrally \u2013 20 mL vial made up to 60 mL with glucose 5% over 6\u20138 hours via syringe driver

    OTHER INFORMATION <\/H4>Oral dosing: Phosphate Sandoz \u2013 16.1 mmol phosphate, 20.4 mmol sodium, 3.1 mmol potassium per tabletIV dosing: (i) Phosphate Polyfusor (500 mL) containing: 50 mmol phosphate, 81 mmol sodium, 9.5 mmol potassium. (ii) Addiphos (20 mL) containing: 40 mmol phosphate, 30 mmol sodium, 30 mmol potassium\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : patients usually need 15\u201320 mmol\/ day in TPNCAV\/VVHD patients usually need 30\u2013 40 mmol\/dayDuring IV phosphate replacement, serum calcium, potassium and phosphate should be monitored 6\u201312 hourly. Repeat the dose within 24 hours if an adequate level has not been achieved. Urinary output should also be monitoredThere is experience giving 15 mmol over 2 hours up to 3 times a dayExcessive doses of phosphate may cause hypocalcaemia and metastatic calcification
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Hypophosphataemia DOSE IN NORMAL RENAL FUNCTION Oral: According<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4625","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4625","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4625"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4625\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4625"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4625"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}